Recent trials demonstrate that sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular mortality in CKD patients by modulating lipid metabolism and mitigating inflammation (2, 5). Here, SLC5A2 is linked to chronic kidney disease.